Figure 2.

Thermal dose characteristics of thermal dose escalation trial of Thrall et al. [108] (A) Comparison of CEM43T₁₀, T₅₀ and T₉₀ values. The trial was designed to deliver approximately a 20-fold difference in CEM43T₉₀ between the low and high dose groups. (B) To achieve this difference in CEM43T₉₀, and CEM43T₁₀, T₅₀ throughout the tumors were higher. (C) Heating times were also longer. N = 21 Low dose group; N = 18 High dose group. Data from the subjects for which physiologic data were reported (Lora-Michaels et al. [109]).